ZACKS·2026-02-03 15:41Group 1: Company Performance - Aldeyra Therapeutics, Inc. (ALDX) has gained approximately 4.8% year-to-date, outperforming the Medical sector, which has seen an average gain of about 0.5% [4] - The Zacks Consensus Estimate for ALDX's full-year earnings has increased by 4.5% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] - Aldeyra Therapeutics, Inc. is currently rated with a Zacks Rank of 2 (Buy), suggesting a positive outlook for the stock [3] Group 2: Industry Context - Aldeyra Therapeutics, Inc. is part of the Medical - Drugs industry, which consists of 141 companies and is currently ranked 159 in the Zacks Industry Rank [6] - Stocks in the Medical - Drugs industry have gained about 1.6% year-to-date, indicating that ALDX is performing better than its industry peers [6] - In contrast, ANI Pharmaceuticals, another stock in the Medical sector, has a year-to-date return of 1.3% and is part of the Medical - Biomedical and Genetics industry, which has declined by 4.4% this year [5][7]